Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCE-A (ShangHai Hengrui Pharma)
- Development stage
- Unknown
- Lead developer
- HenRui Pharmaceuticals
- Modality
- Antibody-Based Therapeutics
01
Overview
TCE-A (ShangHai Hengrui Pharma): sourced facts only. name: "TCE-A binds CD19 and CD20 with nanomolar affinity." [DOI:10.1158/1538-7445.am2026-lb270]; target: "TCE-A binds CD19 and CD20 with nanomolar affinity." [DOI:10.1158/1538-7445.am2026-lb270]; target: "TCE-A binds CD19 and CD20 with nanomolar affinity." [DOI:10.1158/1538-7445.am2026-lb270]; developer: "ShangHai Hengrui Pharmaceuticals Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2026-lb270]; modality: "we developed TCE-A, an Fc-silenced, IgG1-based tri-specific T-cell engager (TCE) simultaneously targeting CD19 andCD20." [DOI:10.1158/1538-7445.am2026-lb270]
02
Targets
Beyond the preview
Go deeper on TCE-A (ShangHai Hengrui Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCE-A (ShangHai Hengrui Pharma).